Navigation Links
Unigene Reports Third Quarter 2011 Financial Results
Date:11/9/2011

ence call and live audio webcast today, November 9, 2011 at 11 a.m., ET to discuss the third quarter 2011 results.

Interested participants and investors may access the conference call at 11 a.m., ET by dialing 800-259-0251 (U.S./Canada) or 617-614-3671 (international); participant code 29191227.  An audio webcast, along with a presentation, can be accessed by logging on to the Investors & Media section under the Events tab of the Unigene web site, www.unigene.com.

A telephonic replay of the call will be available for seven days beginning at 2 p.m., ET on November 9. Access numbers for this replay are 888-286-8010 (U.S./Canada) and 617-801-6888 (international); participant code 44127298.  The webcast replay will remain available in the Investors section of the Unigene Laboratories web site for 30 days.

About Unigene Laboratories, Inc.Unigene Laboratories, Inc. is a leader in the design, delivery, manufacture and development of peptide-based therapeutics. The Company is building a robust portfolio of proprietary partnerships in this expanding drug class based on its Peptelligence™ platform. Peptelligence encompasses extensive intellectual property covering delivery and manufacturing technologies, unsurpassed research and development expertise, and proprietary know-how representing a genuine distinctive competence. Core Peptelligence assets include proprietary oral and nasal peptide delivery technologies, and proprietary, high-yield, scalable and reproducible E. coli-based manufacturing technologies.

Safe Harbor statements under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements, including with respect to clinical studies of our licensees. We have based these forward-looking statements on our current expectations and projections about future events. These forward-looking statements are not guarantees of future performance a
'/>"/>

SOURCE Unigene Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Unigene to Announce Third Quarter 2011 Financial Results on November 9, 2011
2. Webcast Alert: Unigene Laboratories, Inc. (UGNE) Announces Third Quarter 2010 Earnings Conference Call
3. Sinovac Reports Positive Preliminary Phase II Clinical Trial Results for EV71 Vaccine Against Hand, Foot and Mouth Disease
4. GenVec Reports Third Quarter 2011 Financial Results
5. Chindex International, Inc. Reports Financial Results for the Third Quarter and First Nine Months of 2011
6. Allied Healthcare Products Reports First Quarter Loss on Sales Decline
7. ChemoCentryx Reports Clinical Efficacy for CCX354, a Novel CCR1 Inhibitor in a Phase II Study in Patients with Rheumatoid Arthritis
8. Stereotaxis Reports Third Quarter Financial Results
9. Isis Reports Financial Results and Highlights for Third Quarter 2011
10. Alexza Reports 2011 Third Quarter Financial Results and Provides Business Update
11. Anadys Pharmaceuticals Reports Third Quarter 2011 Financial Results and Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements ... announced tender offer by its indirect wholly-owned subsidiary, Sapphire ... of common stock of Solta Medical, Inc. (NASDAQ: ...
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly ... and painless for patients to self-inject prescription drugs in the ... including cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... grow to $220B by 2018, according to analysts.   Many of ...
(Date:1/14/2014)... HILLS, Calif. , Jan. 14, 2014 The Brandeis Medical ... Los Angeles a premier and affordable laser tattoo removal ... special. Dr. Brandeis, focus is in providing high quality cosmetic services ... all patients. " Southern California has ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... SOUTHAMPTON, England, March 24 , ... Completes Phase I Dosing , ... medical needs, announces further clinical trial progress with its ... hypertrophy (BPH) and VA111913 for dysmenorrhoea. The Phase IIa,trial ...
... today announced positive results from a Phase 1 trial ... in vitro anti-pseudomonal activity. The results from ... well tolerated, with a clinical and laboratory safety profile ... toxicity was observed, even at the highest dose regimen ...
Cached Medicine Technology:Vantia Therapeutics' Pipeline Continues to Mature 2Vantia Therapeutics' Pipeline Continues to Mature 3Vantia Therapeutics' Pipeline Continues to Mature 4Calixa Therapeutics Announces Positive Phase 1 Results for CXA-101, a Novel Intravenous Cephalosporin Antibiotic with Excellent Anti-Pseudomonal Activity 2
(Date:4/23/2014)... of endogenous neural precursor cells cannot alone compensate ... the perspective of neural plasticity, Dr. Yun Xiang ... observed the effects of functional electrical stimulation treatment ... of basic fibroblast growth factor and epidermal growth ... side. The researchers found that functional electrical stimulation ...
(Date:4/22/2014)... (Chicago) A recently FDA-approved device has been shown ... as much as 50 percent. When coupled with an ... Rush, the device facilitated the complete elimination of seizures ... in the decade-long clinical trials. , That,s good news ... in the U.S. living with epilepsy whose seizures can,t ...
(Date:4/22/2014)... all lung cancers are small cell lung cancers ... to chemotherapy. However, researchers at Virginia Commonwealth University ... the mechanisms leading to this resistance that may ... primarily by mediating B-cell lymphoma 2 (Bcl-2) family ... Depending on their function, this family of proteins ...
(Date:4/22/2014)... Hopkins scientists have found a way to block abnormal ... of atherosclerosis, the main cause of heart attacks and ... The condition develops when fat builds inside blood vessels ... greatly reducing their ability to feed oxygen-rich blood to ... series of experiments, described April 7 in the journal ...
(Date:4/22/2014)... massive health care spending, a new RAND study concludes ... incentivize pharmaceutical companies and device makers to develop products ... medical technologies and their use, a new study suggests ... medical devices get created in the first place. The ... as little loss of health as possible and to ...
Breaking Medicine News(10 mins):Health News:Newly approved brain stimulator offers hope for individuals with uncontrolled epilepsy 2Health News:Scientists pinpoint protein that could improve small cell lung cancer therapies 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 4Health News:US medical innovation needs smarter incentives to cut health spending, study finds 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 3
... published in the August issue of the American Journal ... multidetector computed tomography (MDCT) in diagnosing// the spread of ... MDCT on 69 patients to examine the efficiency of ... of the 44 cases, while MDCT correctly diagnosed 27. ...
... at a local hospital in Tulungagung, East Java, became ... yesterday.// Runizar Ruesin from the health ministry's bird flu ... with dead chickens. ,Local tests confirmed that ... to deal with bird flu infection and the human ...
... September is the World Heart Day. The theme for the ... all, especially the youth//, to follow a health-friendly regime and ... ,A healthy heart is the foundation to a healthy ... to a healthy life. The booming IT industry, with its ...
... of Fresno, is going through a rough patch, following a ... was enforced after three children from South California took ill ... the State’s charge said "There's a lot of confusion. The ... it's an over-reaction." , ,The State Department of Food ...
... to focus more on healthy eating could be accomplished ... children to eat healthier food could lead to clashes ... has been unveiled by the government which is aimed ... to shorter life expectancies in the younger generation than ...
... Health & Science University's (OHSU) Doernbecher Children's Hospital, the ... to cure Batten disease// is set to get underway ... but deadly neurodegenerative disorder. A phase I trial is ... of its efficacy.,According to the researchers, the transplants of ...
Cached Medicine News:Health News:Healthy Heart for a Hearty Life 2Health News:$67m to Tackle Obesity 2Health News:Stem cell trial to beat Batten Disease 2Health News:Stem cell trial to beat Batten Disease 3
Fine pointed grooved jaws with smooth curve from tip to finger grip style handle. Dull finish....
This forcep was designed to eliminate the occasional tearing of tissue which may occur when grasping the lips of an incision with a traditional. 12 forceps. The rows of blunt teeth are gentle yet pro...
Straight shafts with 1 x 2 teeth. Flat handle with polished finish....
Straight shafts with 90 degrees, 2 x 3 teeth and tying platform. Serrated handle with polished finish. Most popular size or model....
Medicine Products: